Newsfeeds - Spark Newswire

5 minute read

The Daily Biotech Pulse: Priority Review For Amgen’s Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test

Today, 2:17 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)

ABCL

1 minute read

Roth Capital Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $32

By Benzinga Newsdesk

Today, 2:17 PM

Roth Capital analyst Elemer Piros maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and lowers the price target from $38 to $32.

DMAC

5 minute read

58 Biggest Movers From Yesterday

By Lisa Levin

Today, 2:17 PM

Gainers

ALF

3 minute read

Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge

By Lisa Levin

Today, 2:17 PM

Toward the end of trading Tuesday, the Dow traded up 0.04% to 34,295.41 while the NASDAQ rose 0.13% to 14,518.98. The S&P traded flat at 4,290.65.

AUUD

3 minute read

Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher

By Lisa Levin

Today, 2:17 PM

Midway through trading Tuesday, the Dow traded up 0.37% to 34,411.60 while the NASDAQ fell 0.03% to 14,495.75. The S&P also rose, gaining 0.16% to 4,297.63.

AUUD

3 minute read

35 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 2:17 PM

Gainers

ALF

3 minute read

Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results

By Lisa Levin

Today, 2:17 PM

Following the market opening Tuesday, the Dow traded up 0.40% to 34,420.32 while the NASDAQ fell 0.10% to 14,486.23. The S&P also rose, gaining 0.14% to 4,296.59.

AUUD

1 minute read

DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients

By Vandana Singh

Today, 2:17 PM

DiaMedica Therapeutics Inc (NASDAQ:DMAC) has announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease…

DMAC

5 minute read

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout

By Shanthi Rexaline

Today, 2:17 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28)

ABUS

3 minute read

DiaMedica Therapeutics Announces Interim Results From Phase 2 REDUX Study In CKD; Says Results ‘Affirm Biological Activity, Safety and Tolerability of DM199’ And Indicate ‘Statistically and Clinically Significant Reduction in UACR’

By Bill Haddad

Today, 2:17 PM

Results Affirm Biological Activity, Safety and Tolerability of DM199 Consistent with Porcine KLK1 Product in Asia Early Data Indicate Statistically and Clinically Significant Reduction in UACR seen in IgA Nephropathy

DMAC